| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT07566156 Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy… |
Trial sites expanded: 1 -> 9 locations |
| 2026-06-06 | NCT07475806 A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With… |
Trial sites expanded: 5 -> 9 locations |
| 2026-06-05 | NCT07421700 Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With… |
Trial sites expanded: 40 -> 50 locations |
| 2026-06-05 | NCT04960709 Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab… |
Trial sites reduced: 202 -> 196 locations |
| 2026-06-05 | NCT04960709 Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab… |
date change Primary completion moved earlier: 2026-04-30 -> 2026-03-02 |
| 2026-05-29 | NCT06862219 A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer |
Trial sites expanded: 10 -> 13 locations |
| 2026-05-16 | NCT07484022 Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer |
Trial sites expanded: 2 -> 6 locations |
| 2026-05-16 | NCT07475806 A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With… |
Trial sites expanded: 1 -> 5 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-05 | NCT07629700 Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With… | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally… | Locally Advanced Bladder Urothelial Carcinoma | Recruiting |
| NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | Metastatic Urothelial Carcinoma | Recruiting |
| Phase 3 | |||
| NCT07566156 | Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy… | Urothelial Cancer | Recruiting |
| NCT04223856 | Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced… | Urothelial Cancer | Active, Not Recruiting |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab… | Muscle Invasive Bladder Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | High Grade Urothelial Carcinoma | Recruiting |
| NCT05775471 | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical… | Renal Pelvis and Ureter Urothelial Carcinoma | Recruiting |
| NCT07221942 | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line… | Metastatic Urothelial Carcinoma | Recruiting |
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of… | Muscle Invasive Bladder Urothelial Carcinoma | Recruiting |
| NCT07347314 | Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or… | Advanced Small Bowel Adenocarcinoma | Recruiting |
| NCT03547973 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be… | Metastatic Urothelial Cancer | Recruiting |
| NCT06891560 | A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | Adenoid Cystic Carcinoma | Recruiting |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | Metastatic Colorectal Cancer | Recruiting |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular… | Salivary Gland Carcinoma | Recruiting |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab… | Penile Squamous Cell Carcinoma (PSCC) | Recruiting |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of… | Metastatic Bladder Urothelial Carcinoma | Recruiting |
| NCT05868265 | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary… | Urothelial Carcinoma | Recruiting |
| NCT06041503 | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | Adenocarcinoma of the Bladder | Recruiting |
| NCT06311214 | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the… | Advanced Malignant Solid Neoplasm | Recruiting |
| NCT05239624 | Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Urothelial Carcinoma | Recruiting |
| NCT07475806 | A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With… | Muscle-invasive Bladder Cancer | Recruiting |
| NCT06104618 | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous… | Metastatic Penile Squamous Cell Carcinoma | Recruiting |
| NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma | Endometrial Cancer | Not Yet Recruiting |
| NCT07374549 | SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Not Yet Recruiting |
| NCT04754191 | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |